Why is Citius Pharmaceuticals, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-182.74%
EBIT to Interest (avg)
-33.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
1.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
17.32%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.14
EV to EBIT
-0.21
EV to EBITDA
-0.21
EV to Capital Employed
0.15
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-70.72%
ROE (Latest)
-71.62%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
No Trend
Technical Movement
10What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -20.59 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
OPERATING PROFIT(Q)
Highest at USD -8.75 MM
PRE-TAX PROFIT(Q)
Highest at USD -8.94 MM
NET PROFIT(Q)
Highest at USD -8.79 MM
EPS(Q)
Highest at USD -0.8
-7What is not working for the Company
INTEREST(9M)
At USD 0.17 MM has Grown at inf%
ROCE(HY)
Lowest at -53.42%
CASH AND EQV(HY)
Lowest at USD 6.12 MM
Here's what is working for Citius Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD -20.59 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD -8.75 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD -8.94 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD -8.79 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD -0.8
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Citius Pharmaceuticals, Inc.
Interest
At USD 0.17 MM has Grown at inf%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Cash and Eqv
Lowest at USD 6.12 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents






